Cargando…
Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers
Despite almost 30 years of research, no effective vaccine has yet been developed against HIV-1. Probably such a vaccine would need to induce both an effective T cell and antibody response. Any vaccine component focused on inducing humoral immunity requires the HIV-1 envelope (Env) glycoprotein compl...
Autores principales: | Bontjer, Ilja, Melchers, Mark, Tong, Tommy, van Montfort, Thijs, Eggink, Dirk, Montefiori, David, Olson, William C., Moore, John P., Binley, James M., Berkhout, Ben, Sanders, Rogier W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694020/ https://www.ncbi.nlm.nih.gov/pubmed/23840716 http://dx.doi.org/10.1371/journal.pone.0067484 |
Ejemplares similares
-
Targeting HIV-1 envelope glycoprotein trimers to B cells using APRIL improves antibody responses
por: Melchers, M, et al.
Publicado: (2012) -
P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand
por: Melchers, M, et al.
Publicado: (2009) -
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells
por: Melchers, Mark, et al.
Publicado: (2011) -
Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011) -
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity
por: Sliepen, Kwinten, et al.
Publicado: (2015)